Asuragen will incorporate IPA capabilities for enhanced mRNA expression profiling
Redwood City, CA – April 11, 2006 – Ingenuity Systems announces a partnership with Asuragen to provide IPA 3.0 software capabilities to Asuragen’s molecular diagnostic customers.
“Asuragen Service customers will now be able to leverage IPA software for more efficient gathering and analysis of mRNA expression profiling data,” commented Scott Hunicke-Smith, Vice President of Services at Asuragen.
“IPA provides users with the ability to attain more value from experimental results and quickly determine biological context,” commented Peter DiLaura, Vice President, Sales and Customer Support. “This partnership further demonstrates the flexible capabilities of IPA across multiple lab functions.”
IPA is a software application that enables researchers to model, analyze and understand the complex biological systems at the core of life science research. IPA is deployed in most major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally. It supports analysis of all high throughput analysis platforms and is used in virtually all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology, and pharmacogenomics.
IPA is available as a web-delivered, hosted, or deployed solution. Fully functional complimentary trials are available at www.ingenuity.com/trial/start.html.
About Ingenuity Systems®
Ingenuity enables researchers to model, analyze and understand complex biological systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for biologists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotech companies. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan. www.ingenuity.com.
Asuragen, a Spin-Off of Ambion, is comprised of Ambion’s former Diagnostics and Services divisions, along with the formation of a new Discovery group to transform cutting edge research into clinical products. The new Company will have a strong focus around microRNAs and their potential roles as cancer diagnostics. Comprised of over 95 employees from Ambion, Asuragen is empowered with not only scientific expertise but also diagnostic and therapeutic rights to Ambion’s intellectual property.